Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Drugmakers will ask the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on Monday ...

Eli Lilly shares ... billion for diabetes drug Mounjaro and $1.9 billion for Zepbound. That is much higher than a year earlier but short of analysts’ projections of $4.4 billion for Mounjaro and $2.1 ...

The drugs are ... Ricks said. Lilly on Monday approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled by Zepbound and Mounjaro. The company also raised ...

Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation.

Shares of Hims & Hers Health Inc., a telehealth company that provides copycat versions of Novo’s drugs, but not Lilly’s, fell as much as 13% on Thursday morning. Lilly’s shares fell less ...

Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs. The company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products. Lilly said Thursday it will expand a ...

Two primary factors played a role in Lilly's current sell-off. First, investors were not pleased with the financial results for the company's diabetes and obesity care drugs -- Mounjaro and Zepbound.

Indianapolis-based Eli Lilly and Company chose Kenosha County for its latest — and one of its largest — investments. The pharmaceutical giant announced Thursday that it was planning a $3 ...